Safety and efficacy of intravenous thrombolysis in acute ischemic stroke patients with a history of intracranial hemorrhage: A systematic review and meta-analysis
Acute ischemic stroke (AIS) is a fatal and debilitating condition killing 2.7 million people each year worldwide. The most commonly used treatment modality for AIS is intravenous thrombolysis (IVT) with alteplase which is indicated for those presenting within 4.5 h of onset. Due to a lack of reliabl...
Gespeichert in:
Veröffentlicht in: | Clinical neurology and neurosurgery 2022-04, Vol.215, p.107205-107205, Article 107205 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 107205 |
---|---|
container_issue | |
container_start_page | 107205 |
container_title | Clinical neurology and neurosurgery |
container_volume | 215 |
creator | Gajurel, Bikram Prasad Nepal, Gaurav Kharel, Sanjeev Yadav, Jayant Kumar Yadav, Sushil Kumar Shing, Yow Ka Goeschl, Stella Thapaliya, Sahil |
description | Acute ischemic stroke (AIS) is a fatal and debilitating condition killing 2.7 million people each year worldwide. The most commonly used treatment modality for AIS is intravenous thrombolysis (IVT) with alteplase which is indicated for those presenting within 4.5 h of onset. Due to a lack of reliable evidence on harm or benefit, the 2019 American Heart Association/American Stroke Association (AHA/ASA) guidelines consider a history of previous intracranial hemorrhage (ICH) as potentially harmful and no longer an absolute contraindication for IVT in patients with AIS, and the U.S. Food and Drug Administration (FDA) removed chronic ICH as a specific contraindication for IVT from the label in 2015. Despite a shift in guidelines, physicians frequently face the dilemmatic choice whether to administer IVT in this subset of patients due to the risk of symptomatic intracranial hemorrhage (SICH). The benefit of IVT in such patients has not been thoroughly investigated, and there are only a few studies on the subject in the literature to date. We conducted the present meta-analysis in an aim to provide solid evidence on the efficacy and safety of IVT for treating AIS in patients with a history of remote ICH. Our meta-analysis found that IVT improves functional outcomes in AIS patients with prior remote ICH without increasing SICH or all-cause mortality. These findings may contribute to the decision-making process for IVT administration in AIS patients.
•The most commonly used treatment modality for acute ischemic stroke (AIS) is intravenous thrombolysis (IVT) with alteplase.•The 2019 AHA/ASA guideline consider a history of previous intracerebral hemorrhage (ICH) as potentially harmful.•Physicians are frequently faced with the difficult decision of whether to administer IVT in this subset of patients due to the possible complications.•Our meta-analysis found that IVT improves functional outcomes in AIS patients with prior remote ICH without increasing SICH or all-cause mortality.•These findings may contribute to the decision-making process for IVT administration in AIS patients. |
doi_str_mv | 10.1016/j.clineuro.2022.107205 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2641512851</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0303846722000865</els_id><sourcerecordid>2643260898</sourcerecordid><originalsourceid>FETCH-LOGICAL-c396t-69125af7e674fbd9d0af8cdb9e32192dc96034a042f6dcff50044b4de85d8e7d3</originalsourceid><addsrcrecordid>eNqFkctu1DAUhi0EokPhFSpLbNhk8C2Ow4qq4iZVYgGsLcc-Zjwk8WA7rfI6PCnuTAsSG1aWjr__XP4foQtKtpRQ-Xq_tWOYYUlxywhjtdgx0j5CG6o61sheqsdoQzjhjRKyO0PPct4TQjiX6ik64y0nUgi5Qb--GA9lxWZ2GLwP1tgVR4_DXJK5gTkuGZdditMQxzWHXD-wsUsBHLLdwRQsziXFH4APpgSYS8a3oeywwbuQS0x_m9lk5mBGXEUxpZ35Dm_wJc5rLjBVqcUJbgLcHjeZoJjGzOY48jl64s2Y4cX9e46-vX_39epjc_35w6ery-vG8l6WejNlrfEdyE74wfWOGK-sG3rgjPbM2V4SLgwRzEtnvW8JEWIQDlTrFHSOn6NXp76HFH8ukIue6o0wjmaGaoNmUtCWMtXSir78B93HJdV9jxRnkqheVUqeKJtizgm8PqQwmbRqSvRdinqvH1LUdynqU4pVeHHffhkmcH9kD7FV4O0JgOpHdS3pbKv5FlxIYIt2Mfxvxm9perWC</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2643260898</pqid></control><display><type>article</type><title>Safety and efficacy of intravenous thrombolysis in acute ischemic stroke patients with a history of intracranial hemorrhage: A systematic review and meta-analysis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>ProQuest Central UK/Ireland</source><creator>Gajurel, Bikram Prasad ; Nepal, Gaurav ; Kharel, Sanjeev ; Yadav, Jayant Kumar ; Yadav, Sushil Kumar ; Shing, Yow Ka ; Goeschl, Stella ; Thapaliya, Sahil</creator><creatorcontrib>Gajurel, Bikram Prasad ; Nepal, Gaurav ; Kharel, Sanjeev ; Yadav, Jayant Kumar ; Yadav, Sushil Kumar ; Shing, Yow Ka ; Goeschl, Stella ; Thapaliya, Sahil</creatorcontrib><description>Acute ischemic stroke (AIS) is a fatal and debilitating condition killing 2.7 million people each year worldwide. The most commonly used treatment modality for AIS is intravenous thrombolysis (IVT) with alteplase which is indicated for those presenting within 4.5 h of onset. Due to a lack of reliable evidence on harm or benefit, the 2019 American Heart Association/American Stroke Association (AHA/ASA) guidelines consider a history of previous intracranial hemorrhage (ICH) as potentially harmful and no longer an absolute contraindication for IVT in patients with AIS, and the U.S. Food and Drug Administration (FDA) removed chronic ICH as a specific contraindication for IVT from the label in 2015. Despite a shift in guidelines, physicians frequently face the dilemmatic choice whether to administer IVT in this subset of patients due to the risk of symptomatic intracranial hemorrhage (SICH). The benefit of IVT in such patients has not been thoroughly investigated, and there are only a few studies on the subject in the literature to date. We conducted the present meta-analysis in an aim to provide solid evidence on the efficacy and safety of IVT for treating AIS in patients with a history of remote ICH. Our meta-analysis found that IVT improves functional outcomes in AIS patients with prior remote ICH without increasing SICH or all-cause mortality. These findings may contribute to the decision-making process for IVT administration in AIS patients.
•The most commonly used treatment modality for acute ischemic stroke (AIS) is intravenous thrombolysis (IVT) with alteplase.•The 2019 AHA/ASA guideline consider a history of previous intracerebral hemorrhage (ICH) as potentially harmful.•Physicians are frequently faced with the difficult decision of whether to administer IVT in this subset of patients due to the possible complications.•Our meta-analysis found that IVT improves functional outcomes in AIS patients with prior remote ICH without increasing SICH or all-cause mortality.•These findings may contribute to the decision-making process for IVT administration in AIS patients.</description><identifier>ISSN: 0303-8467</identifier><identifier>EISSN: 1872-6968</identifier><identifier>DOI: 10.1016/j.clineuro.2022.107205</identifier><identifier>PMID: 35306446</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Administration, Intravenous ; Alteplase ; Bleed ; Boolean ; Brain Ischemia - complications ; Brain Ischemia - drug therapy ; Confidence intervals ; Decision making ; FDA approval ; Fibrinolytic Agents - adverse effects ; Gender ; Hemorrhage ; Humans ; ICH ; Intracerebral hemorrhage ; Intracranial hemorrhage ; Intracranial Hemorrhages - chemically induced ; Intracranial Hemorrhages - drug therapy ; Intravenous administration ; Ischemia ; Ischemic Stroke ; Meta-analysis ; Mortality ; Patients ; Statistical analysis ; Stroke ; Stroke - etiology ; Systematic review ; Thrombolysis ; Thrombolytic Therapy - adverse effects ; Treatment Outcome</subject><ispartof>Clinical neurology and neurosurgery, 2022-04, Vol.215, p.107205-107205, Article 107205</ispartof><rights>2022 Elsevier B.V.</rights><rights>Copyright © 2022 Elsevier B.V. All rights reserved.</rights><rights>2022. Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c396t-69125af7e674fbd9d0af8cdb9e32192dc96034a042f6dcff50044b4de85d8e7d3</citedby><cites>FETCH-LOGICAL-c396t-69125af7e674fbd9d0af8cdb9e32192dc96034a042f6dcff50044b4de85d8e7d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2643260898?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35306446$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gajurel, Bikram Prasad</creatorcontrib><creatorcontrib>Nepal, Gaurav</creatorcontrib><creatorcontrib>Kharel, Sanjeev</creatorcontrib><creatorcontrib>Yadav, Jayant Kumar</creatorcontrib><creatorcontrib>Yadav, Sushil Kumar</creatorcontrib><creatorcontrib>Shing, Yow Ka</creatorcontrib><creatorcontrib>Goeschl, Stella</creatorcontrib><creatorcontrib>Thapaliya, Sahil</creatorcontrib><title>Safety and efficacy of intravenous thrombolysis in acute ischemic stroke patients with a history of intracranial hemorrhage: A systematic review and meta-analysis</title><title>Clinical neurology and neurosurgery</title><addtitle>Clin Neurol Neurosurg</addtitle><description>Acute ischemic stroke (AIS) is a fatal and debilitating condition killing 2.7 million people each year worldwide. The most commonly used treatment modality for AIS is intravenous thrombolysis (IVT) with alteplase which is indicated for those presenting within 4.5 h of onset. Due to a lack of reliable evidence on harm or benefit, the 2019 American Heart Association/American Stroke Association (AHA/ASA) guidelines consider a history of previous intracranial hemorrhage (ICH) as potentially harmful and no longer an absolute contraindication for IVT in patients with AIS, and the U.S. Food and Drug Administration (FDA) removed chronic ICH as a specific contraindication for IVT from the label in 2015. Despite a shift in guidelines, physicians frequently face the dilemmatic choice whether to administer IVT in this subset of patients due to the risk of symptomatic intracranial hemorrhage (SICH). The benefit of IVT in such patients has not been thoroughly investigated, and there are only a few studies on the subject in the literature to date. We conducted the present meta-analysis in an aim to provide solid evidence on the efficacy and safety of IVT for treating AIS in patients with a history of remote ICH. Our meta-analysis found that IVT improves functional outcomes in AIS patients with prior remote ICH without increasing SICH or all-cause mortality. These findings may contribute to the decision-making process for IVT administration in AIS patients.
•The most commonly used treatment modality for acute ischemic stroke (AIS) is intravenous thrombolysis (IVT) with alteplase.•The 2019 AHA/ASA guideline consider a history of previous intracerebral hemorrhage (ICH) as potentially harmful.•Physicians are frequently faced with the difficult decision of whether to administer IVT in this subset of patients due to the possible complications.•Our meta-analysis found that IVT improves functional outcomes in AIS patients with prior remote ICH without increasing SICH or all-cause mortality.•These findings may contribute to the decision-making process for IVT administration in AIS patients.</description><subject>Administration, Intravenous</subject><subject>Alteplase</subject><subject>Bleed</subject><subject>Boolean</subject><subject>Brain Ischemia - complications</subject><subject>Brain Ischemia - drug therapy</subject><subject>Confidence intervals</subject><subject>Decision making</subject><subject>FDA approval</subject><subject>Fibrinolytic Agents - adverse effects</subject><subject>Gender</subject><subject>Hemorrhage</subject><subject>Humans</subject><subject>ICH</subject><subject>Intracerebral hemorrhage</subject><subject>Intracranial hemorrhage</subject><subject>Intracranial Hemorrhages - chemically induced</subject><subject>Intracranial Hemorrhages - drug therapy</subject><subject>Intravenous administration</subject><subject>Ischemia</subject><subject>Ischemic Stroke</subject><subject>Meta-analysis</subject><subject>Mortality</subject><subject>Patients</subject><subject>Statistical analysis</subject><subject>Stroke</subject><subject>Stroke - etiology</subject><subject>Systematic review</subject><subject>Thrombolysis</subject><subject>Thrombolytic Therapy - adverse effects</subject><subject>Treatment Outcome</subject><issn>0303-8467</issn><issn>1872-6968</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkctu1DAUhi0EokPhFSpLbNhk8C2Ow4qq4iZVYgGsLcc-Zjwk8WA7rfI6PCnuTAsSG1aWjr__XP4foQtKtpRQ-Xq_tWOYYUlxywhjtdgx0j5CG6o61sheqsdoQzjhjRKyO0PPct4TQjiX6ik64y0nUgi5Qb--GA9lxWZ2GLwP1tgVR4_DXJK5gTkuGZdditMQxzWHXD-wsUsBHLLdwRQsziXFH4APpgSYS8a3oeywwbuQS0x_m9lk5mBGXEUxpZ35Dm_wJc5rLjBVqcUJbgLcHjeZoJjGzOY48jl64s2Y4cX9e46-vX_39epjc_35w6ery-vG8l6WejNlrfEdyE74wfWOGK-sG3rgjPbM2V4SLgwRzEtnvW8JEWIQDlTrFHSOn6NXp76HFH8ukIue6o0wjmaGaoNmUtCWMtXSir78B93HJdV9jxRnkqheVUqeKJtizgm8PqQwmbRqSvRdinqvH1LUdynqU4pVeHHffhkmcH9kD7FV4O0JgOpHdS3pbKv5FlxIYIt2Mfxvxm9perWC</recordid><startdate>202204</startdate><enddate>202204</enddate><creator>Gajurel, Bikram Prasad</creator><creator>Nepal, Gaurav</creator><creator>Kharel, Sanjeev</creator><creator>Yadav, Jayant Kumar</creator><creator>Yadav, Sushil Kumar</creator><creator>Shing, Yow Ka</creator><creator>Goeschl, Stella</creator><creator>Thapaliya, Sahil</creator><general>Elsevier B.V</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>202204</creationdate><title>Safety and efficacy of intravenous thrombolysis in acute ischemic stroke patients with a history of intracranial hemorrhage: A systematic review and meta-analysis</title><author>Gajurel, Bikram Prasad ; Nepal, Gaurav ; Kharel, Sanjeev ; Yadav, Jayant Kumar ; Yadav, Sushil Kumar ; Shing, Yow Ka ; Goeschl, Stella ; Thapaliya, Sahil</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c396t-69125af7e674fbd9d0af8cdb9e32192dc96034a042f6dcff50044b4de85d8e7d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Administration, Intravenous</topic><topic>Alteplase</topic><topic>Bleed</topic><topic>Boolean</topic><topic>Brain Ischemia - complications</topic><topic>Brain Ischemia - drug therapy</topic><topic>Confidence intervals</topic><topic>Decision making</topic><topic>FDA approval</topic><topic>Fibrinolytic Agents - adverse effects</topic><topic>Gender</topic><topic>Hemorrhage</topic><topic>Humans</topic><topic>ICH</topic><topic>Intracerebral hemorrhage</topic><topic>Intracranial hemorrhage</topic><topic>Intracranial Hemorrhages - chemically induced</topic><topic>Intracranial Hemorrhages - drug therapy</topic><topic>Intravenous administration</topic><topic>Ischemia</topic><topic>Ischemic Stroke</topic><topic>Meta-analysis</topic><topic>Mortality</topic><topic>Patients</topic><topic>Statistical analysis</topic><topic>Stroke</topic><topic>Stroke - etiology</topic><topic>Systematic review</topic><topic>Thrombolysis</topic><topic>Thrombolytic Therapy - adverse effects</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gajurel, Bikram Prasad</creatorcontrib><creatorcontrib>Nepal, Gaurav</creatorcontrib><creatorcontrib>Kharel, Sanjeev</creatorcontrib><creatorcontrib>Yadav, Jayant Kumar</creatorcontrib><creatorcontrib>Yadav, Sushil Kumar</creatorcontrib><creatorcontrib>Shing, Yow Ka</creatorcontrib><creatorcontrib>Goeschl, Stella</creatorcontrib><creatorcontrib>Thapaliya, Sahil</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical neurology and neurosurgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gajurel, Bikram Prasad</au><au>Nepal, Gaurav</au><au>Kharel, Sanjeev</au><au>Yadav, Jayant Kumar</au><au>Yadav, Sushil Kumar</au><au>Shing, Yow Ka</au><au>Goeschl, Stella</au><au>Thapaliya, Sahil</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety and efficacy of intravenous thrombolysis in acute ischemic stroke patients with a history of intracranial hemorrhage: A systematic review and meta-analysis</atitle><jtitle>Clinical neurology and neurosurgery</jtitle><addtitle>Clin Neurol Neurosurg</addtitle><date>2022-04</date><risdate>2022</risdate><volume>215</volume><spage>107205</spage><epage>107205</epage><pages>107205-107205</pages><artnum>107205</artnum><issn>0303-8467</issn><eissn>1872-6968</eissn><abstract>Acute ischemic stroke (AIS) is a fatal and debilitating condition killing 2.7 million people each year worldwide. The most commonly used treatment modality for AIS is intravenous thrombolysis (IVT) with alteplase which is indicated for those presenting within 4.5 h of onset. Due to a lack of reliable evidence on harm or benefit, the 2019 American Heart Association/American Stroke Association (AHA/ASA) guidelines consider a history of previous intracranial hemorrhage (ICH) as potentially harmful and no longer an absolute contraindication for IVT in patients with AIS, and the U.S. Food and Drug Administration (FDA) removed chronic ICH as a specific contraindication for IVT from the label in 2015. Despite a shift in guidelines, physicians frequently face the dilemmatic choice whether to administer IVT in this subset of patients due to the risk of symptomatic intracranial hemorrhage (SICH). The benefit of IVT in such patients has not been thoroughly investigated, and there are only a few studies on the subject in the literature to date. We conducted the present meta-analysis in an aim to provide solid evidence on the efficacy and safety of IVT for treating AIS in patients with a history of remote ICH. Our meta-analysis found that IVT improves functional outcomes in AIS patients with prior remote ICH without increasing SICH or all-cause mortality. These findings may contribute to the decision-making process for IVT administration in AIS patients.
•The most commonly used treatment modality for acute ischemic stroke (AIS) is intravenous thrombolysis (IVT) with alteplase.•The 2019 AHA/ASA guideline consider a history of previous intracerebral hemorrhage (ICH) as potentially harmful.•Physicians are frequently faced with the difficult decision of whether to administer IVT in this subset of patients due to the possible complications.•Our meta-analysis found that IVT improves functional outcomes in AIS patients with prior remote ICH without increasing SICH or all-cause mortality.•These findings may contribute to the decision-making process for IVT administration in AIS patients.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>35306446</pmid><doi>10.1016/j.clineuro.2022.107205</doi><tpages>1</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0303-8467 |
ispartof | Clinical neurology and neurosurgery, 2022-04, Vol.215, p.107205-107205, Article 107205 |
issn | 0303-8467 1872-6968 |
language | eng |
recordid | cdi_proquest_miscellaneous_2641512851 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete; ProQuest Central UK/Ireland |
subjects | Administration, Intravenous Alteplase Bleed Boolean Brain Ischemia - complications Brain Ischemia - drug therapy Confidence intervals Decision making FDA approval Fibrinolytic Agents - adverse effects Gender Hemorrhage Humans ICH Intracerebral hemorrhage Intracranial hemorrhage Intracranial Hemorrhages - chemically induced Intracranial Hemorrhages - drug therapy Intravenous administration Ischemia Ischemic Stroke Meta-analysis Mortality Patients Statistical analysis Stroke Stroke - etiology Systematic review Thrombolysis Thrombolytic Therapy - adverse effects Treatment Outcome |
title | Safety and efficacy of intravenous thrombolysis in acute ischemic stroke patients with a history of intracranial hemorrhage: A systematic review and meta-analysis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T15%3A03%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20and%20efficacy%20of%20intravenous%20thrombolysis%20in%20acute%20ischemic%20stroke%20patients%20with%20a%20history%20of%20intracranial%20hemorrhage:%20A%20systematic%20review%20and%20meta-analysis&rft.jtitle=Clinical%20neurology%20and%20neurosurgery&rft.au=Gajurel,%20Bikram%20Prasad&rft.date=2022-04&rft.volume=215&rft.spage=107205&rft.epage=107205&rft.pages=107205-107205&rft.artnum=107205&rft.issn=0303-8467&rft.eissn=1872-6968&rft_id=info:doi/10.1016/j.clineuro.2022.107205&rft_dat=%3Cproquest_cross%3E2643260898%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2643260898&rft_id=info:pmid/35306446&rft_els_id=S0303846722000865&rfr_iscdi=true |